Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

StatusCompleted
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 369 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial completed
    • Study sites revised (240)
    v369
  2. Minor Study completion date: Sep 30, 2025 to Mar 31, 2026v368
  3. Minor Study completion date: Apr 8, 2025 to Sep 30, 2025
    • Interventions: 3-Dimensional Conformal Radiation Therapy (Radiation), Biospecimen Collection (Procedure), Chest Radiography (Procedure), Computed… to 3-Dimensional Conformal Radiation Therapy (Radiation), Biospecimen Collection (Procedure), Chest Radiography (Procedure), Computed…
    • Study sites revised (240)
    v367
  4. Minor Study completion date: Jan 31, 2025 to Apr 8, 2025
    • Start date: Oct 30, 2006 to Nov 6, 2006
    • Interventions: 3-Dimensional Conformal Radiation Therapy (Radiation), Dactinomycin (Biological), Doxorubicin Hydrochloride (Drug), Therapeutic… to 3-Dimensional Conformal Radiation Therapy (Radiation), Biospecimen Collection (Procedure), Chest Radiography (Procedure), Computed…
    • Study description expanded, about 22 words
    v366
  5. Minor Study completion date: Jan 10, 2024 to Jan 31, 2025v365
Show 45 earlier versionsHide 45 earlier versions
  1. Minor Study completion date: Dec 31, 2024 to Jan 10, 2024
    • Study sites revised (240)
    v364
  2. Minor Study sites: 221 to 240
    • Study completion date: Dec 31, 2023 to Dec 31, 2024
    • Interventions: 3-dimensional conformal radiation therapy (Radiation), dactinomycin (Biological), doxorubicin hydrochloride (Drug), therapeutic… to 3-Dimensional Conformal Radiation Therapy (Radiation), Dactinomycin (Biological), Doxorubicin Hydrochloride (Drug), Therapeutic…
    v363
  3. Minor Study completion date: Dec 31, 2023v362
  4. Re-verified, no change to tracked fieldsv361
  5. Minor Trial status: Completed to Active, Not Recruiting
    • Primary completion date: Dec 2014 to Dec 31, 2014
    • Study completion date: Sep 2015 to not stated
    • Start date: Oct 2006 to Oct 30, 2006
    v360
  6. Notable Results first posted: May 15, 2017
    • Primary endpoints revised (2)
    • Secondary endpoints revised (2)
    v359
  7. Minor Trial status: Active, Not Recruiting to Completed
    • Primary completion date changed from estimate of Aug 2017 to Dec 2014
    • Study completion date: Sep 2015
    v358
  8. Minor Study sites: 215 to 221
    • Secondary endpoints revised (2)
    v357
  9. Notable Primary completion date: Sep 2014 to Aug 2017
    • Secondary endpoints revised (2)
    v356
  10. Minor Enrollment target: estimated 875 to confirmed 808v355
  11. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 218 to 215
    v354
  12. Notable Primary completion date: Jun 2016 to Sep 2014v353 Show 8 more changesShow less
    • Start date: Jun 2006 to Oct 2006
    • Primary endpoints revised (2)
    • Study sites: 211 to 218
    • Interventions: dactinomycin (Biological), doxorubicin hydrochloride (Drug), external beam radiation therapy (Radiation), therapeutic conventional surgery… to 3-dimensional conformal radiation therapy (Radiation), dactinomycin (Biological), doxorubicin hydrochloride (Drug), therapeutic…
    • Eligibility criteria shortened, about 79 words
    • Secondary endpoints: details revised at 2 of 2 entries
    • Study title revised
    • Study description expanded, about 3 words
  13. Minor Study sites revised (211)v352
  14. Re-verified, no change to tracked fieldsv351
  15. Minor Site contacts updated at 1 of 211 sitesv350
  16. Minor Study sites: 210 to 211v349
  17. Minor Study sites: 209 to 210v348
  18. Minor Site contacts updated at 1 of 209 sitesv347
  19. Minor Site contacts updated at 1 of 209 sitesv346
  20. Re-verified, no change to tracked fieldsv345
  21. Minor Study sites revised (209)v344
  22. Minor Site contacts updated at 1 of 209 sitesv343
  23. Minor Site contacts updated at 1 of 209 sitesv342
  24. Notable Primary completion date: Feb 2011 to Jun 2016v341 Show 7 more changesShow less
    • Enrollment target: 600 to 875
    • Study sites: 206 to 209
    • Start date: Oct 2006 to Jun 2006
    • Interventions: conventional surgery (Procedure), dactinomycin (Biological), doxorubicin hydrochloride (Drug), radiation therapy (Radiation), vincristine… to dactinomycin (Biological), doxorubicin hydrochloride (Drug), external beam radiation therapy (Radiation), therapeutic conventional surgery…
    • Eligibility criteria expanded, about 54 words
    • Study description shortened, about 10 words
    • Study title revised
  25. Minor Study sites revised (206)v340
  26. Minor Site contacts updated at 1 of 206 sitesv339
  27. Re-verified, no change to tracked fieldsv338
  28. Minor Study sites: 205 to 206v337
  29. Minor Study sites: 204 to 205v336
  30. Minor Study sites: 205 to 204v335
  31. Re-verified, no change to tracked fieldsv334
  32. Minor Study sites revised (205)v333
  33. Re-verified, no change to tracked fieldsv332
  34. Minor Site contacts updated at 1 of 205 sitesv331
  35. Minor Site contacts updated at 1 of 205 sitesv330
  36. Re-verified, no change to tracked fieldsv329
  37. Minor Site contacts updated at 1 of 205 sitesv328
  38. Minor Site contacts updated at 1 of 205 sitesv327
  39. Re-verified, no change to tracked fieldsv326
  40. Minor Site contacts updated at 1 of 205 sitesv325
  41. Re-verified, no change to tracked fieldsv324
  42. Minor Study sites: 204 to 205v323
  43. Minor Study sites: 190 to 204v322
  44. Minor Study sites revised (190)v321
  45. Re-verified, no change to tracked fieldsv320
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase III trial is studying vincristine, dactinomycin, and doxorubicin with or without radiation therapy or observation only to see how well they work in treating patients undergoing surgery for newly diagnosed stage I, stage II, or stage III Wilms' tumor. Drugs used in chemotherapy, such as vincristine, dactinomycin, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors.Giving these treatments after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the tumor may not need additional treatment until it progresses. In this case, observation may be sufficient.
Trial Details
NCT Number NCT00352534
Lead Sponsor Children's Oncology Group
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)
Stage I Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor
Related terms Wilms Tumor
Enrollment 808 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov